The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
Volume 343:310-316 August 3, 2000 Number 5
NextNext

Effect of Intravenous Omeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers
James Y.W. Lau, M.B., B.S., Joseph J.Y. Sung, M.D., Kenneth K.C. Lee, Ph.D., Man-yee Yung, B.N., Simon K.H. Wong, M.B., Ch.B., Justin C.Y. Wu, M.B., Ch.B., Francis K.L. Chan, M.D., Enders K.W. Ng, M.B., Ch.B., Joyce H.S. You, Pharm.D., C.W. Lee, M.Phil., Angus C.W. Chan, M.B., Ch.B., and S.C. Sydney Chung, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Libby, E. D.

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background After endoscopic treatment of bleeding peptic ulcers, bleeding recurs in 15 to 20 percent of patients.

Methods We assessed whether the use of a high dose of a proton-pump inhibitor would reduce the frequency of recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. Patients with actively bleeding ulcers or ulcers with nonbleeding visible vessels were treated with an epinephrine injection followed by thermocoagulation. After hemostasis had been achieved, they were randomly assigned in a double-blind fashion to receive omeprazole (given as a bolus intravenous injection of 80 mg followed by an infusion of 8 mg per hour for 72 hours) or placebo. After the infusion, all patients were given 20 mg of omeprazole orally per day for eight weeks. The primary end point was recurrent bleeding within 30 days after endoscopy.

Results We enrolled 240 patients, 120 in each group. Bleeding recurred within 30 days in 8 patients (6.7 percent) in the omeprazole group, as compared with 27 (22.5 percent) in the placebo group (hazard ratio, 3.9; 95 percent confidence interval, 1.7 to 9.0). Most episodes of recurrent bleeding occurred during the first three days, which made up the infusion period (5 in the omeprazole group and 24 in the placebo group, P<0.001). Three patients in the omeprazole group and nine in the placebo group underwent surgery (P=0.14). Five patients (4.2 percent) in the omeprazole group and 12 (10 percent) in the placebo group died within 30 days after endoscopy (P=0.13).

Conclusions After endoscopic treatment of bleeding peptic ulcers, a high-dose infusion of omeprazole substantially reduces the risk of recurrent bleeding.


Source Information

From the Departments of Surgery (J.Y.W.L., M.Y., S.K.H.W., E.K.W.N., A.C.W.C., S.C.S.C.), Medicine and Therapeutics (J.J.Y.S., J.C.Y.W., F.K.L.C.), and Pharmacy (K.K.C.L., J.H.S.Y., C.W.L.), Chinese University of Hong Kong, Shatin, Hong Kong, China.

Address reprint requests to Dr. Chung at the Department of Surgery, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, China, or at sydneychung{at}cuhk.edu.hk.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.